- Home
- CDAQ vs ATHA Comparison
CDAQ vs ATHA Comparison
Compare CDAQ & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDAQ
- ATHA
- Stock Information
- Founded
- CDAQ 2021
- ATHA 2011
- Country
- CDAQ United States
- ATHA United States
- Employees
- CDAQ N/A
- ATHA N/A
- Industry
- CDAQ Blank Checks
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- CDAQ Finance
- ATHA Health Care
- Exchange
- CDAQ Nasdaq
- ATHA Nasdaq
- Market Cap
- CDAQ 112.9M
- ATHA 93.5M
- IPO Year
- CDAQ 2021
- ATHA 2020
- Fundamental
- Price
- CDAQ $10.82
- ATHA $0.54
- Analyst Decision
- CDAQ
- ATHA Buy
- Analyst Count
- CDAQ 0
- ATHA 3
- Target Price
- CDAQ N/A
- ATHA $22.00
- AVG Volume (30 Days)
- CDAQ 16.3K
- ATHA 1.5M
- Earning Date
- CDAQ 01-01-0001
- ATHA 08-01-2024
- Dividend Yield
- CDAQ N/A
- ATHA N/A
- EPS Growth
- CDAQ N/A
- ATHA N/A
- EPS
- CDAQ 0.09
- ATHA N/A
- Revenue
- CDAQ N/A
- ATHA N/A
- Revenue This Year
- CDAQ N/A
- ATHA N/A
- Revenue Next Year
- CDAQ N/A
- ATHA N/A
- P/E Ratio
- CDAQ $122.57
- ATHA N/A
- Revenue Growth
- CDAQ N/A
- ATHA N/A
- 52 Week Low
- CDAQ $10.45
- ATHA $0.52
- 52 Week High
- CDAQ $12.50
- ATHA $4.30
- Technical
- Relative Strength Index (RSI)
- CDAQ 52.00
- ATHA 15.43
- Support Level
- CDAQ $10.74
- ATHA $3.17
- Resistance Level
- CDAQ $10.82
- ATHA $3.34
- Average True Range (ATR)
- CDAQ 0.00
- ATHA 0.24
- MACD
- CDAQ 0.01
- ATHA -0.32
- Stochastic Oscillator
- CDAQ 100.00
- ATHA 0.72
About CDAQ Compass Digital Acquisition Corp.
Compass Digital Acquisition Corp is a blank check company.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.